alpha-Ergostenol | 632-32-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: alpha-Ergostenol
• 英文别名: 17-(5,6-dimethylheptan-2-yl)-10,13-dimethyl-2,3,4,5,6,7,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 632-32-6
• 化学式: C₂₈H₄₈O
• 分子量: 400.7
• InChiKey: AWYDNKRGSOPYQB-UHFFFAOYSA-N

物化性质

• 熔点：
  130-131°
• 比旋光度：
  D16 +11° (c = 0.9 in methanol); 546 -10.2° (c = 1 in methanol)
• 沸点：
  463.29°C (rough estimate)
• 密度：
  0.9575 (rough estimate)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 储存条件：
  存储条件：2-8℃，密封保存，置于干燥处。

文献信息

• Linear polyethylenimine-sterol conjugates for gene delivery
  申请人：The University of Utah Research Foundation

  公开号：US20040137050A1

  公开（公告）日：2004-07-15

  Linear polyethylenimine was modified with sterols, such as cholesterol, in three different geometries: linear shaped (L), T-shaped (T), and a combined linear- and T-shaped (LT), to result in linear polyethylenimine-sterol conjugates. These conjugates were mixed with nucleic acids to form complexes for delivery of the nucleic acids into cells. Mammalian cells transfected with these complexes showed protein expression levels higher than linear polyethylenimine alone, and twice that of branched polyethylenimine, but without any significant loss in cell viability. Methods of making these compositions and methods of using them for gene delivery are also described.

  线性聚乙烯亚胺被固醇（如胆固醇）以三种不同的几何形状进行改性：线性形状（L）、T形状（T）和线性和T形状的组合（LT），从而形成线性聚乙烯亚胺-固醇共轭物。这些共轭物与核酸混合形成复合物，用于将核酸传递到细胞中。转染这些复合物的哺乳动物细胞显示出比单独使用线性聚乙烯亚胺更高的蛋白表达水平，且比支化聚乙烯亚胺高出一倍，但没有任何显著的细胞存活率损失。还描述了制备这些组合物的方法以及将其用于基因传递的方法。
• Implants for localized drug delivery and methods of use thereof
  申请人：The Regents of the University of California

  公开号：US10912933B2

  公开（公告）日：2021-02-09

  Provided herein is an implant for delivering a hydrophobic active agent to a target tissue. The implant may include a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to a hydrophobic active agent, and a silicone tubing having a wall permeable to the active agent, wherein a first length of the silicone tubing is affixed to the first surface of the scaffold, wherein the two ends of the silicone tubing extend from the first surface, and wherein a path outlined by a second length of the tubing within the first length is circuitous. Also provided is a method of using the implant to locally deliver a hydrophobic active agent to a target tissue, and kits that find use in performing the present method.

  本文提供了一种向目标组织输送疏水活性剂的植入物。该植入物可包括界定第一表面和与第一表面相对的第二表面的支架，其中支架基本上不渗透疏水活性剂，以及具有可渗透活性剂壁的硅胶管，其中硅胶管的第一长度贴在支架的第一表面上，其中硅胶管的两端从第一表面延伸，并且第一长度内的第二长度的硅胶管所勾勒的路径是迂回的。此外，还提供了一种使用植入物向目标组织局部递送疏水活性剂的方法，以及可用于实施本方法的试剂盒。
• COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY
  申请人：Miv Therapeutics Inc.

  公开号：EP2136856A1

  公开（公告）日：2009-12-30
• IMPLANTS FOR LOCALIZED DRUG DELIVERY AND METHODS OF USE THEREOF
  申请人：The Regents of the University of California

  公开号：EP3183026B1

  公开（公告）日：2019-10-30
• Compounds exhibiting efflux inhibitor activity and composition and uses thereof
  申请人：Wempe Fitzpatrick Michael

  公开号：US20070254859A1

  公开（公告）日：2007-11-01

  At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.